Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic

Author:

Machida MasakiORCID,Nakamura Itaru,Kojima Takako,Saito Reiko,Nakaya Tomoki,Hanibuchi TomoyaORCID,Takamiya Tomoko,Odagiri Yuko,Fukushima Noritoshi,Kikuchi HiroyukiORCID,Amagasa ShihoORCID,Watanabe Hidehiro,Inoue ShigeruORCID

Abstract

Vaccination could be a key protective measure against coronavirus disease 2019 (COVID-19), and it is important to understand the acceptability of the COVID-19 vaccine among the general public. However, there is no study on the acceptance of a COVID-19 vaccine in Japan. Therefore, this study aimed to describe the COVID-19 vaccine acceptance and hesitancy situation in Japan and assess the factors associated with such issues. This was a cross-sectional study based on an internet survey completed by 2956 people. Participants were asked to indicate how likely they were to get vaccinated for COVID-19. In addition, the participants responded to questions regarding sociodemographic factors, attitudes, and beliefs regarding COVID-19 infection and vaccination. The proportion of participants with a high likelihood of getting a COVID-19 vaccine was 62.1%. Multiple logistic regression analysis showed that vaccine acceptance was lower among several sociodemographic groups, such as women, adults aged 20–49 years, and those with a low-income level. Several psychological factors, especially the perceived effectiveness of the COVID-19 vaccine, and willingness to protect others by getting oneself vaccinated, were associated with vaccine acceptance. Our results indicate that the perceived effectiveness of the vaccine and willingness to protect others may play an important role in the acceptance of the COVID-19 vaccine.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference46 articles.

1. Coronavirus Disease (COVID-19) Pandemichttps://www.who.int/emergencies/diseases/novel-coronavirus-2019

2. Coronavirus Disease (COVID-19): Herd Immunity, Lockdowns and COVID-19https://www.who.int/news-room/q-a-detail/herd-immunity-lockdowns-and-covid-19

3. Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. primary and community healthcare

4. Community Mitigation Guidelines to Prevent Pandemic Influenza — United States, 2017

5. Developing a SARS-CoV-2 Vaccine at Warp Speed

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3